Please assess the completion status of the following clinical trial:

Trial Title: Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of OCD~* Currently on a stable and adequate dose of an SRI~* Sufficient severity of symptoms to warrant additional augmentation treatment~Exclusion Criteria:~* Medical or psychiatric conditions that would make participation in the study unsafe~* Currently receiving psychotherapy elsewhere at the time of study entry~* Previously (within 12 weeks prior to study entry) attended 8 or more sessions of EX/RP within a 2-month period or received at least 4 weeks of antipsychotic augmentation while on an adequate SRI dose~* Currently being treated with an SRI for the first time and has not yet responded, but has not tried another SRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Participants will receive treatment with risperidone
- 2 (Type: ACTIVE_COMPARATOR): Participants will receive exposure and ritual prevention therapy (EX/RP)
- 3 (Type: PLACEBO_COMPARATOR): Participants will receive treatment with the placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).